Reinventing Medical Strategies with Data-driven Insights
"[H1 is] really the only place where I can go and get information about any therapeutic area. It’s not curated specifically to one disease or one drug. It’s comprehensive. It’s the entire medical landscape across the globe, so I’m not limited to anything."
Perhaps one of the most consequential shifts in medical affairs has been the change in focus from quantity to quality – including quality of data and quality of KOL engagements. Johnson & Johnson’s Jennifer Wheeler has seen firsthand just how many opportunities data insights have opened up for her medical affairs team, from medical education and scientific exchange to assisting with identifying diverse patient populations for clinical trials.
Click below to listen to the full interview: